Skip to main content
. 2024 Feb 17;51(5):1268–1286. doi: 10.1007/s00259-024-06640-x

Fig. 1.

Fig. 1

The number of phase 1 or early phase 1 interventional studies with therapeutic radionuclides and molecular or functional targeting mechanisms recorded in ClinicalTrials.gov per year, as of end of 2022. Electron emitters and alpha emitters are split in (a) and (b), and in (c), the results have been separated according to carrier instead of emitter